USPH

Over the past six months, USPH reported Q2 2026 results in August 2026, exceeding revenue expectations with 8.5% year-on-year growth to $214.1 million, but missing adjusted EPS estimates at $0.75 per share, with net income attributable to shareholders declining by 20.1%. Strategic acquisitions included a twelve-clinic physical therapy practice on July 1, 2026, expanding its footprint and adding $12 million in annual revenue, and earlier in 2026, two 10-year strategic alliances to integrate 70 clinics into hospital networks, along with the acquisition of an eight-clinic practice and an industrial injury prevention business. Executive appointments included a new Chief Financial Officer in August 2026 and Myra Davis to the Board of Directors effective October 1, 2026. Analyst sentiment has been generally positive, with a 'Moderate Buy' consensus rating in September 2026 and some analysts raising price targets. As of early October 2026, USPH shares increased by 8.09% over the last six months and 15.09% over the last three months.